Clinical trial NCT02060526: Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease
Official title: A Randomized, Controlled, Open-label, Multicenter, Phase IIb Safety and Efficacy Study of rhHNS (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Early Stage Mucopolysaccharidosis Type IIIA Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Sanfilippo Syndrome
Keywords: sulfoglucosamine sulfohydrolase (SGSH)
recombinant human heparan N-sulfatase (rhHNS)
Hunter's Syndrome
Shire HGT
Lysosomal Storage Disease (LSD)
Sanfilippo Syndrome Type A (Sanfilippo A)
enzyme replacement therapy (ERT)
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2014-02-12
Enrollment: 21
Sex: ALL
Minimum age (years): 12
Maximum age (years): 48
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sanfilippo syndrome Type A, or Mucopolysaccharidosis (MPS) IIIA, is a rare lysosomal storage disease caused by deficiency of the enzyme heparan N-sulfatase (sulfamidase). In the absence of this enzyme, there is an accumulation of the glycosaminoglycan, heparan sulfate, resulting in progressive neurodegeneration. Symptoms are usually first noted in the 1st or 2nd year of life, although definitive diagnosis is often delayed, with an average age of diagnosis of 4.5 years. The disease is characterized by developmental delays initially, followed by neurological developmental arrest, then regression. These developmental deficits are typically associated with severe behavioral disturbances. Patients have a significantly reduced lifespan, with few surviving beyond the 2nd or 3rd decade.

The purpose of this study is to evaluate the safety and efficacy of recombinant human heparan-N-sulfatase (rhHNS) in pediatric patients with Early Stage Mucopolysaccharidosis Type III A Disease.

Detailed description: No effective, disease-modifying therapies are currently approved as treatments for this devastating and disabling disease.

Shire Human Genetic Therapies (Shire HGT) is developing an enzyme replacement therapy (ERT) recombinant human heparan-N-sulfatase (rhHNS) for patients with MPS IIIA. rhHNS is being administered into the cerebrospinal fluid (CSF) via an surgically implanted intrathecal drug delivery device (IDDD), because when administered intravenously (IV) it does not cross the blood brain barrier (BBB).

This study will evaluate the effect of 48 weeks of rhHNS treatment on the clinical course of MPS IIIA, using cognitive function as the primary outcome measure. The trial will evaluate 2 dosing regimens of rhHNS administered via an IDDD in comparison with a no treatment control group. Patients will be randomized 1:1:1 to either of the treatment groups or the no treatment group. Treatment will be administered in an open-label manner. The safety and tolerability profile of rhHNS will continue to be evaluated in this study.

Eligibility criteria: Inclusion Criteria:

Each patient must meet the following criteria to be enrolled in this study.

1. Documented MPS IIIA diagnosis
2. Age ≥12 months and ≤48 months
3. The patient has a DQ score ≥60%
4. The patient is medically stable, in the opinion of the Investigator, and able to accommodate the protocol requirements, including travel, assessments, and IDDD surgery, without placing an undue burden on the patient/patient's family
5. The patient's parent(s) or legally authorized representative(s) must have voluntarily signed and dated an Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient's parent(s), or legally authorized representative(s). Consent of the patient's parent(s) or legally authorized representative(s) must be obtained prior to the start of any study procedures.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

1. The presence of significant non-MPS IIIA related CNS impairment or behavioral disturbances that would confound the scientific integrity or interpretation of study assessments, as determined by the Investigator.
2. The presence of at least one S298P mutation in SGSH, associated with attenuated disease OR there is documentation of the S298P mutation in a sibling affected by MPS IIIA, provided parental consent is obtained to use this information.
3. The presence of relatively attenuated MPS IIIA disease in an older sibling, defined as preservation of any speech beyond the age of 10 years.
4. Visual or hearing impairment sufficient, in the clinical judgment of the investigator, to preclude cooperation with neurodevelopmental testing. Use of hearing aids is permitted.
5. In the opinion of the Investigator, the patient is assessed as having an unacceptably high risk for anesthesia due to airway compromise, drug hypersensitivity, or other conditions (such as neuroleptic malignant syndrome, malignant hyperthermia, or other anesthesia-related concerns).
6. The patient has a history of poorly controlled seizure disorder.
7. The patient is currently receiving psychotropic or other medications, which in the Investigator's opinion would be likely to substantially confound test results.
8. The patient has a history of bleeding disorder or is unable to abstain from medications that, in the opinion of the investigator, place them at risk of bleeding following surgery or LP.
9. The patient participated in a clinical trial of another investigational medicinal product, within the 30 days prior to the study (or within 5 elimination half lives of the investigational product), or is currently enrolled in another study that involves an investigational drug or device. NOTE: Nutritional supplements, including genistein are permitted if they are taken or administered outside the context of a formal investigation.
10. The patient has received a hematopoietic stem cell or bone marrow transplant, or gene therapy.
11. The patient has a condition that is contraindicated as described in the SOPH-A-PORT Mini S-IDDD
12. The patient's parent(s) or patient's legally authorized representative(s) is/are unable to understand the nature, scope, and possible consequences of the study, or do/does not agree to comply with the protocol defined schedule of assessments.
13. The patient is unable to comply with the protocol (eg, has a clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, or otherwise unlikely to complete the study) or is, in the opinion of the Investigator, otherwise unsuited for the study.
14. The patient has any item (braces, tattoos, etc.) which would exclude the patient from being able to undergo MRI according to local Institutional Policy, or the patient has any other situation that would exclude the patient from undergoing any other procedure required in this study.

Primary outcomes:
measure: Number of Participants With Overall Response Using Bayley Scales of Infant Development Assessment Third Edition (BSID-III)
timeFrame: Baseline (Week 0) up to Week 48
Secondary outcomes:
measure: Number of Participants With Serious Adverse Events (SAE)
timeFrame: Baseline (Week 0) up to Week 52
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
timeFrame: Baseline (Week 0) up to Week 52
measure: Number of Participants With Positive Anti-recombinant Human Heparan-N-Sulfatase (rhHNS) Antibody in Serum at Week 48
timeFrame: Baseline (Week 0) up to Week 48
measure: Change From Baseline in Vineland Adaptive Behavior Scales Second Edition (VABS-II) Development Quotient (DQ) Score at Week 48
timeFrame: Baseline (Week 0), Week 48
measure: Change From Baseline in Development Quotient (DQ) Using Bayley Scales of Infant Development Assessment Third Edition (BSID-III) at Week 48
timeFrame: Baseline (Week 0), Week 48
measure: Change From Baseline in Total Cortical Grey Matter Volume at Week 48
timeFrame: Baseline (Week 0), Week 48
measure: Change From Baseline in Concentration of Glycosaminoglycan (GAG) in Cerebrospinal Fluid (CSF) at Week 48
timeFrame: Baseline (Week 0), Week 48
measure: Change From Baseline in Concentration of GAG in Urine at Week 48
timeFrame: Baseline (Week 0), Week 48
measure: Concentration of Recombinant Human Heparan-N-Sulfatase (rhHNS) in Cerebrospinal Fluid (CSF)
timeFrame: Pre-dose, 4, 48 hours on Week 0 and Week 48
measure: Maximum Observed Drug Concentration (Cmax) of Recombinant Human Heparan-N-Sulfatase (rhHNS) in Serum
timeFrame: Predose, 0.5 h, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, and 48 h post-dose on Week 0 and Week 48
Other outcomes:
Locations:
city: Torrance
country: United States
facility: Los Angeles Biomedical Research
state: California
city: Minneapolis
country: United States
facility: University of Minnesota Department of Pediatrics
state: Minnesota
city: Chapel Hill
country: United States
facility: University of North Carolina
state: North Carolina
city: Buenos Aires
country: Argentina
facility: Hospital Universitario Austral A Unidad de Investigacion
city: Le Kremlin-Bicêtre
country: France
facility: Chu Bicetre
state: Paris
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg Eppendorf
city: Monza
country: Italy
facility: U.O.S Malattie Metaboliche Rare Clinical Pediatrica
city: Amsterdam
country: Netherlands
facility: Academisch Medisch Centrum
city: Barcelona
country: Spain
facility: Hospital Vall D'Hebron
city: London
country: United Kingdom
facility: Great Ormond Street Hospital
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
citation: Wijburg FA, Whitley CB, Muenzer J, Gasperini S, Del Toro M, Muschol N, Cleary M, Sevin C, Shapiro E, Bhargava P, Kerr D, Alexanderian D. Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial. Mol Genet Metab. 2019 Feb;126(2):121-130. doi: 10.1016/j.ymgme.2018.10.006. Epub 2018 Oct 24.